Citrome L (noviembre de 2013). «Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?». Int. J. Clin. Pract.67 (11): 1089-104. PMID24016209. doi:10.1111/ijcp.12298.
Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998). «Which bioequivalence study for a racemic drug? Application to milnacipran». European Journal of Drug Metabolism and Pharmacokinetics23 (2): 166-71. PMID9725476. doi:10.1007/bf03189334.
Citrome L (noviembre de 2013). «Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?». Int. J. Clin. Pract.67 (11): 1089-104. PMID24016209. doi:10.1111/ijcp.12298.
Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998). «Which bioequivalence study for a racemic drug? Application to milnacipran». European Journal of Drug Metabolism and Pharmacokinetics23 (2): 166-71. PMID9725476. doi:10.1007/bf03189334.